Is Himax Technologies Inc (HIMX) undervalued when accounting for its future growth?

Josh Kim
December 17, 2016

Himax Technologies, Inc.'s (HIMX) stock price ended its day with a loss of -2.79% and finalized at the price of $6.28. The company's market cap is $5.34 Billion, and the average volume is $1.14 Million. The company's past year sales total was 177.98 Million. The company traded 10.54 million shares versus it average capacity of 3.8 million shares. The stock revealed the change of -2.79% with down momentum. Relative volume is ratio between current volume and 3-month average value, intraday adjusted. This means that when accounting for its growth Himax Technologies's stock can be viewed a very good value based on its fundamentals.

During the last trading session, the expensive price at which share traded, recorded at $6.51 and cheapest price at share trade was noted at $5.97.

For the Current Quarter, the growth estimate for Himax Technologies, Inc.is 125%, while for the Next Quarter the stock growth estimate is 0%.

According to the Recommendation Trends of the stock polled by Zacks Investment Research for this month, the company has a consensus recommendation of 2.71 out of the scale from 1 to 5 where 1 stands for Strong Buy and 5 means Strong Sell.

The Stock fell -7.16% and closed its last trading session at $3.37.

During last one month it showed the change of -17.91%. The median estimate represents a +50.68% increase from the last price of 3.37. A low ATR value correlates with a weaker trend movement. The analysts believe that the company stock price could grow as high as $12. Beta factor, which measures the riskiness of the security, was observed as 1.13.

ZIOPHARM Oncology Inc (ZIOP) Broker Price Targets For The Coming Week
ORBCOMM, Inc. (NASDAQ:ORBC) topped its 52-week high price of $10.98 on Aug 3, 2016 and 52-Week Low Price of $6.51 on Dec 18, 2015. Boston Partners bought a new position in shares of Clovis Oncology during the second quarter worth approximately $1,540,000.

Analysts give HIMX a mean recommendation of 2.30.

The price-to-earnings ratio of Himax Technologies stands at 20.6, compared to the industry average this already suggests that it could be undervalued.But seeing as Himax Technologies is thought of as a high growth stock, to properly value it we must also account for its earnings growth by using calculation called PEG ratio. The company beat the analyst EPS Estimate with the difference of $0.02. This year company's Earnings per Share (EPS) growth is -372.90% and next year's estimated EPS growth is 70.42%.

Is HIMX's share price justified by its earnings growth? It has a dividend yield of 2.07%. Finally, analysts shed their light over the SYRX price targets; maintaining price high target of 1.75 while at average the price target was 1.75 in contrast with the current price of 0.24. Have a look at back 1 month ago, consensus EPS forecast was seen at $0.08. Whereas they predicted High and Low Earnings Estimate as $0.1 and $0.01 respectively. During period one month ago, consensus EPS forecast was decided at $0.36.

Many brokerage firms are involved in issuing their ratings on Himax Technologies, Inc. Majority ranked Overweight from the pool of analysts.

When we look at the Analyst Recommendations of the stock, the company has 1.8 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.

Other reports by MyHealthBowl

Discuss This Article

FOLLOW OUR NEWSPAPER